BioSpace News Archive

Fresenius Kabi announced today it has received FDA approval for Daptomycin for Injection and the product is available immediately for customers in the United States

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced that three posters, focusing on preclinical and preliminary clinical biomarker data of PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting

AACR 2018 Annual Meeting includes 40-plus abstracts covering QIAGEN Sample to Insight solutions

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”) today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the “Notes”), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes.

Sensient Technologies Corporation (NYSE: SXT) will hold its conference call to discuss 2018 first quarter results at 10:00 a.m. CDT on Wednesday, April 25, 2018.